FDA Approval Advances Basal Insulin
Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.
By
Kathryn Wighton
March 27, 2026
Clinical Scorecard: FDA Approval Advances Basal Insulin
At a Glance
Category Detail
Condition Type 2 Diabetes Key Mechanisms Once-weekly basal insulin injection to improve glycemic control Target Population Adults with uncontrolled type 2 diabetes Care Setting Outpatient
Key Highlights
First once-weekly basal insulin approved for type 2 diabetes Reduces injections from seven to one per week Administered using the Awiqli FlexTouch device Efficacy demonstrated in HbA1c reduction Safety profile consistent with daily basal insulin Guideline-Based Recommendations
Diagnosis
Evaluate HbA1c levels for diagnosis of type 2 diabetes Management
Use insulin icodec-abae as an adjunct to diet and exercise Monitoring & Follow-up
Regular monitoring of HbA1c levels to assess glycemic control Risks
Potential for hypoglycemia and other insulin-related adverse effects Patient & Prescribing Data
Adults with uncontrolled type 2 diabetes
Combination with mealtime insulin or oral antidiabetic agents may be beneficial
Clinical Best Practices
Educate patients on the use of the Awiqli FlexTouch device Monitor for efficacy and safety during treatment Adjust dosage based on individual patient response References
